KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Co-Diagnostics (CODX) FCF Margin (2017 - 2025)

Historic FCF Margin for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to 4113.14%.

  • Co-Diagnostics' FCF Margin fell 29583400.0% to 4113.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 6263.08%, marking a year-over-year decrease of 58964300.0%. This contributed to the annual value of 763.78% for FY2024, which is 4195800.0% down from last year.
  • Latest data reveals that Co-Diagnostics reported FCF Margin of 4113.14% as of Q3 2025, which was down 29583400.0% from 5333.55% recorded in Q2 2025.
  • Over the past 5 years, Co-Diagnostics' FCF Margin peaked at 60.58% during Q1 2021, and registered a low of 17576.88% during Q1 2025.
  • In the last 5 years, Co-Diagnostics' FCF Margin had a median value of 244.26% in 2023 and averaged 2126.25%.
  • As far as peak fluctuations go, Co-Diagnostics' FCF Margin skyrocketed by 28866400bps in 2024, and later crashed by -156761500bps in 2025.
  • Over the past 5 years, Co-Diagnostics' FCF Margin (Quarter) stood at 23.32% in 2021, then tumbled by -1417bps to 307.04% in 2022, then soared by 52bps to 147.48% in 2023, then plummeted by -3671bps to 5561.02% in 2024, then increased by 26bps to 4113.14% in 2025.
  • Its last three reported values are 4113.14% in Q3 2025, 5333.55% for Q2 2025, and 17576.88% during Q1 2025.